Bone markers.
The recent development of specific and sensitive biochemical markers reflecting the overall rate of bone formation and bone resorption, has markedly improved the non-invasive assessment of bone turnover in various metabolic bone diseases, especially osteoporosis. The immunoassay of human osteocalcin recognizing the intact molecule and its major proteolytic fragment, along with that of bone alkaline phosphatase, are currently the most sensitive markers to assess bone formation. For bone resorption, the total urinary excretion of pyridinoline crosslinks measured by high pressure liquid chromatography has shown its superiority over all other markers for the clinical assessment of osteoporosis. The recent development of immunoassays recognizing either the free pyridinoline crosslinks or pyridinoline crosslinked-type I collagen peptides in urine and serum should allow a broad use of this sensitive resorption marker. Recent studies, some of them still in progress, define the clinical use of these markers: first, to improve the prognostic assessment of post-menopausal women in combination with bone mass measurement, i.e. their risk of developing osteoporosis and, ultimately, fractures and, second, to monitor the efficacy of anti-resorption drugs.
Garnero
P
P
INSERM Research Unit 403, Hôpital E. Herriot, Lyon, France.
Delmas
P D
PD
D000328:Adult; D000368:Aged; D000469:Alkaline Phosphatase / Q000032:analysis; D015415:Biomarkers / Q000097:blood / Q000652:urine; D016723:Bone Remodeling / Q000502:physiology*; D001842:Bone and Bones / Q000737:chemistry; D005260:Female; D006801:Humans; D008875:Middle Aged; D015675:Osteocalcin / Q000097:blood; D010012:Osteogenesis / Q000502:physiology*; D010024:Osteoporosis / Q000378:metabolism* / Q000473:pathology / Q000628:therapy; D011379:Prognosis
D015415:Biomarkers; D015675:Osteocalcin; D000469:Alkaline Phosphatase